Adrenal cortical carcinoma

被引：8

作者：

Boushey R.P. ^{[1
]}

Dackiw A.P.B. ^{[1
]}

机构：

[1] Department of Surgical Oncology, Section of Endocrine Surgery, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Suite 3-130, Toronto, M5G 2M9, ON

来源：

Current Treatment Options in Oncology | 2001年 / 2卷 / 4期

关键词：

Adrenal Tumor; Gossypol; Inferior Vena Cava; Suramin; Varicocele;

D O I：

10.1007/s11864-001-0029-1

中图分类号：

学科分类号：

摘要：

Adrenal cortical carcinoma is a rare endocrine tumor, and complete surgical resection is the only potentially curative treatment. Accurate preoperative biochemical and radiographic evaluation of the patient who presents with an adrenal mass optimizes patient management and facilitates a complete margin-negative resection of the primary tumor—the most important prognostic variable for long-term survival. Response to mitotane or chemotherapy is modest in patients with advanced disease. It is hoped that an improved understanding of the molecular pathogenesis of this challenging tumor will lead to the development of novel treatment strategies. © 2001, Current Science Inc.

引用

页码：355 / 364

页数：9

共 43 条

[41]

Bukowski R.M., Wolfe M., Levine H.S., Et al., Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group Study, J Clin Oncol, 11, pp. 161-165, (1993)

[42]

Hesketh P.J., McCaffrey R.P., Finkel H.E., Et al., Cisplatinbased treatment of adrenal cortical carcinoma, Cancer Treat Rep, 71, pp. 222-224, (1987)

[43]

Johnson D.H., Greco F.A., Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16), Cancer, 58, pp. 2198-2202, (1986)

← 1 2 3 4 5 →